Mutation analysis and clinical outcome in patients with a greater than 2-fold rise in BCR-ABL according to the disease phase at the start of imatinib
. | . | . | Acquired resistance . | . | . | . | ||
|---|---|---|---|---|---|---|---|---|
| Disease phase at the start of imatinib . | More than 2-fold rise in BCR-ABL (%) . | No. patients . | AP or BC . | Loss of CHR . | Cytogenetic relapse . | No acquired resistance . | ||
| Blast crisis, n = 5 | 3 (60) | |||||||
| Mutation | 1 | 1 | — | — | — | |||
| No mutation | 2 | 2 | — | — | — | |||
| Accelerated phase, n = 27 | 15 (56) | |||||||
| Mutation | 12 | 6 | 2 | 4 | — | |||
| No mutation | 3 | 1 | — | 1 | 1 | |||
| Late chronic phase, n = 48 | 18 (38) | |||||||
| Mutation | 11 | 6 | 2 | 1 | 2 | |||
| No mutation | 7 | 2 | — | 2 | 3 | |||
| Early chronic phase, n = 134 | 20 (15) | |||||||
| Mutation | 10 | 3 | 3 | 3 | 1 | |||
| No mutation | 10 | 1 | — | 4 | 5 | |||
. | . | . | Acquired resistance . | . | . | . | ||
|---|---|---|---|---|---|---|---|---|
| Disease phase at the start of imatinib . | More than 2-fold rise in BCR-ABL (%) . | No. patients . | AP or BC . | Loss of CHR . | Cytogenetic relapse . | No acquired resistance . | ||
| Blast crisis, n = 5 | 3 (60) | |||||||
| Mutation | 1 | 1 | — | — | — | |||
| No mutation | 2 | 2 | — | — | — | |||
| Accelerated phase, n = 27 | 15 (56) | |||||||
| Mutation | 12 | 6 | 2 | 4 | — | |||
| No mutation | 3 | 1 | — | 1 | 1 | |||
| Late chronic phase, n = 48 | 18 (38) | |||||||
| Mutation | 11 | 6 | 2 | 1 | 2 | |||
| No mutation | 7 | 2 | — | 2 | 3 | |||
| Early chronic phase, n = 134 | 20 (15) | |||||||
| Mutation | 10 | 3 | 3 | 3 | 1 | |||
| No mutation | 10 | 1 | — | 4 | 5 | |||
Late chronic phase indicates patients who commenced imatinib 12 months or more after diagnosis. Early chronic phase indicates patients who commenced imatinib less than 12 months after diagnosis. Dashes indicate that there were no patients in the category.